9. Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatric Infectious Disease Journal, 2006, 25(10): 912-919.
10. Usonis V, Meriste S, Bakasenas V, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheriatetanus-acellular pertussisinactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12–18 months. Vaccine, 2005, 23: 2602–2606.
17. Wang Y, Qi Y, Xu W, et al. Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction. Hum Vaccin Immunother, 2020, 16(10): 2559-2564.
18. Zhuang F C , Mao Z A , Jiang L M , et al. [Long-term immunogenicity and effectiveness of live attenuated hepatitis A vaccine (H2-strain)-a study on the result of 15 years' follow up].[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2010, 31(12):1332-1335.